Burkitt’s Lymphoma (BL) is a rare form of B-cell non-Hodgkin’s lymphoma. It is the most aggressive form of lymphoma and is driven by a c-MYC translocation induced by the Epstein-Barr virus (EBV). In endemic regions, malaria is a common cofactor that allows EBV infect host cells for longer periods of time. EBV uses two phases, the latent and lytic cycles, to establish long term infection and invasion of host cells. EBV driven mononucleosis is compared with the B-cell proliferation in BL. Treatment strategies for BL include high-intensity chemotherapy along with stem cell transplantation as a secondary form of treatment. Treatment for EBV is currently being investigated as a method to prevent BL. In this review, a comparison of treatment costs for low-income countries and high-income counties is discussed to emphasize the importance of efficient and affordable healthcare.